drugset / Trial / NCT04882774
Telemonitoring to Treat Group 2 Pulmonary Hypertension
Phase 2
Withdrawn
Mardi Gomberg -Maitland MD, MSc
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · collabOhio State University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in combination with the fluid management plan while those with improved pressures maintain their fluid management plan for an additional 16 weeks.
Timeline
- Start
- 2023-04
- Primary completion
- 2025-04
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil diethanolamine | Unknown | 6 mg | Oral |